Your browser doesn't support javascript.
loading
Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin's lymphoma
Galán, L; Sánchez, A. C; Cantos, B; Provencio, M.
Affiliation
  • Galán, L; Hospital Universitario Puerta de Hierro. Majadahonda. Spain
  • Sánchez, A. C; Hospital Universitario Puerta de Hierro. Majadahonda. Spain
  • Cantos, B; Hospital Universitario Puerta de Hierro. Majadahonda. Spain
  • Provencio, M; Hospital Universitario Puerta de Hierro. Majadahonda. Spain
Clin. transl. oncol. (Print) ; 12(5): 384-386, mayo 2010. tab, ilus
Article in English | IBECS | ID: ibc-124086
Responsible library: ES1.1
Localization: BNCS
ABSTRACT
Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) accounts for approximately 5% of Hodgkin's lymphoma, presents with early-stage disease and has an indolent course. Treatment is not well established. We present a patient diagnosed with NLPHL and treated with Rituximab second-line therapy after chemotherapy (AU)
Subject(s)
Search on Google
Add to My VHL
Print
XML
Collection: National databases / Spain Database: IBECS Main subject: Hodgkin Disease / Lymphocyte Activation / Antibodies, Monoclonal Limits: Aged / Female / Humans Language: English Journal: Clin. transl. oncol. (Print) Year: 2010 Document type: Article Institution/Affiliation country: Hospital Universitario Puerta de Hierro/Spain
Search on Google
Add to My VHL
Print
XML
Collection: National databases / Spain Database: IBECS Main subject: Hodgkin Disease / Lymphocyte Activation / Antibodies, Monoclonal Limits: Aged / Female / Humans Language: English Journal: Clin. transl. oncol. (Print) Year: 2010 Document type: Article Institution/Affiliation country: Hospital Universitario Puerta de Hierro/Spain